

Photocure ASA 2nd Quarter 2026 Results

July 29, 2026

Dan Schneider, President and CEO

Priyam Shah, VP IR

Dick Peters, VP Finance & IT



THE
BLADDER CANCER
COMPANY



Disclaimer

By reading this company presentation (the "Presentation") or attending any meeting or oral presentation held in relation thereto, you (the "Recipient") agree to be bound by the following terms, conditions and limitations.

The Presentation has been produced by Photocure ASA (the "Company") for information purposes only and does not in itself constitute, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction. The distribution of this Presentation may be restricted by law in certain jurisdictions, and the Recipient should inform itself about, and observe, any such restriction. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction.

The Recipient acknowledges that it will be solely responsible for its own assessment of the Company, the market and the market position of the Company and that it will conduct its own analysis and be solely responsible for forming its own view of the potential future performance of the Company's business. The Company shall not have any liability whatsoever (in negligence or otherwise) arising directly or indirectly from the use of this Presentation or its contents, including but not limited to any liability for errors, inaccuracies, omissions or misleading statements in this Presentation, or violation of distribution restrictions.

The Presentation will be used during an oral presentation and is therefore not a complete summary of the presentation held. Further, it is not the intention to provide, and the Recipient may not rely on the Presentation as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects. Several factors could adversely affect the business, legal or financial position of the Company or the value of its securities. For a further description of other relevant risk factors, we refer to the Company's annual report for 2025. Should one or more of these or other risks and uncertainties materialize, actual results may vary significantly from those described in this Presentation.

This Presentation contains certain forward-looking statements relating to inter alia the business, financial performance and results of the Company and the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts. Any forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts and are subject to risks, uncertainties and other factors that may cause actual results and events to be materially different from those expected or implied by the forward-looking statements. The Company cannot provide any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of opinions expressed in this Presentation or the actual occurrence of forecasted developments.

This Presentation speaks as at the date set out on herein. Neither the delivery of this Presentation nor any further discussions of the Company shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The Company does not assume any obligation to update or revise the Presentation or disclose any changes or revisions to the information contained in the Presentation (including in relation to forward-looking statements).

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of Norwegian courts.

Strategic Priorities & Initiatives



THE
BLADDER CANCER
COMPANY



Continue to grow Hexvix®/Cysview® sales and increase Company profitability

- Provide and deliver on financial guidance, continue generating operating leverage
- Accelerate ForTec Mobile BLC usage
- Drive additional account reactivations in U.S. and image quality upgrades in Europe
- Increase penetration in Priority Growth Markets in Europe
- Leverage Olympus' launch of new HD BLC system in Nordics/EU



Establish BLC® as the definitive diagnostic standard in bladder cancer care and improve access

- Position blue light cystoscopy (BLC) as the primary diagnostic tool to facilitate earlier use of new NMIBC therapeutics
- Support reclassification of BLC equipment in the U.S
- Collaborate with BLC equipment manufacturers who plan to enter the U.S.
- Build adoption for Richard Wolf's interim Flex BLC solution in Europe; launch new HD Flex BLC system globally once developed



Expand and diversify global product portfolio in uro-oncology

- Assess new opportunities in NMIBC and adjacent uro-oncology indications, including biomarkers, AI, and emerging precision medicine technologies
- Leverage Photocure's established global commercial infrastructure to expand into precision diagnostics within the broader uro-oncology segment

2nd Quarter 2026 Highlights: 1/2

Continued Growth and Execution on Key Initiatives



THE
BLADDER CANCER
COMPANY

Product Revenue Q2 **+11%** (constant currency)

NOK 140.0 million

Regional Performance YoY

- North America product revenue up **12%** (constant currency), units up **10%** (**rigid units up 13%**) - reaching all time high in North America
 - ForTec Mobile Solution growth favorably impacts the increase, while flex decline and FX partly offsets growth.
- Europe product revenue up **10%** (constant currency), units up **8%**

Increasing number of U.S. accounts: **436** (**+20% YoY**)

- 4 new towers installed
- 2 upgrades in existing accounts

Executing on plan in Europe

- 87 Olympus BLC Visera Elite-III systems installed since launch (in Q1 2025)

Adjusted EBITDA **NOK 27.2 million**

Reported EBITDA NOK -2.0 million

Adjusted EBITDA margin:

- **19% in Q2 2026 (20% in Q2 2025)**
- **15% YTD 2026 (14% YTD 2025)**

We continue forecasting improved operating leverage for 2026 while investing in growth opportunities

Biz Dev expense: NOK 21.8 million

Strong Balance Sheet:

- At the end of Q2 NOK 162.4 million in cash and equivalents, inclusive of partial collection of Asieris milestone;
- No term debt

2nd Quarter 2026 Highlights: 2/2

Continued Growth and Execution on Key Initiatives



THE
BLADDER CANCER
COMPANY

Business & Partnership News

Acquisition of Vesica Health Inc., strengthening Photocure's leadership in bladder cancer diagnostics. (June 4)

Photocure and Artera to partner in joint research on digital pathology AI test evaluation for Bladder Cancer (June 8)

FDA confirmed its plans to Photocure, to issue a proposed order to reclassify OAY equipment under its own initiative, starting in H2 2026. (April 13)

System blue BLC, developed by Richard Wolf, received **market approval in China** to work in synergy with Hexvix (April 17)

Stryker has introduced a CE-marked **blue light-compatible system in Europe** (May 7)

Cevira news: first shipment into China & first global prescription (June 5)

Events & Publications

Blue Light Cystoscopy demonstrates **cost neutrality through reduced recurrence** in real-world BRAVO study publication (April 7)

New health economic methodology published: comparing **cost-effectiveness of BLC versus NBI** imaging technology in bladder cancer (May 4)

AUA 2026 congress: presentation of two Photocure-supported abstracts. These new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study (May 15-18)



THE
BLADDER CANCER
COMPANY

Segment Trends

North America and Europe markets


Strong Sales Performance in Both Regions in Q2

Q2 Hexvix/Cysview Unit Sales by Region (Last 3 Years)




THE
BLADDER CANCER
COMPANY

North America



Europe



Strong Growth in U.S. Accounts Using Cysview

20% YoY growth in Q2 2026




THE
BLADDER CANCER
COMPANY

Active* U.S. Accounts

(Rolling 12 Months through Current Reported Quarter)

+20% YoY growth



* Active account is defined as an account with at least one order during the last 12 months accounts include rigid-only, multi- or dual-towers, flex-only, mobile tower, and evaluation



THE
BLADDER CANCER
COMPANY

Growth Initiatives

U.S. BLC Market Offers Significant Growth Opportunity with Strong Near-Term Upside



THE
BLADDER CANCER
COMPANY

Addressable Market Expansion Triggers and Photocure Initiatives


- 1 Additional Rigid Manufacturers / FDA Reclassification**
 - Initiatives:** FDA reclassification / alternative OEM pathways
 - Progress:** FDA confirmed to begin reclassification process in H2 2026 / OEM partners to update
- 2 Flexible Surveillance**
 - Initiatives:** Richard Wolf partnership to develop Flex Cystoscopes
 - Progress:** Interim solution launched in EU – scalable global solution expected in 2027
- 3 Reimbursement**
 - Initiatives:** CMS dialogue ongoing / co-sponsored congressional bill on expanded access
 - Progress:** FAIC Act filed (Dunn/Soto) in March 2026

Bladder Cancer Market Access

U.S. incidence¹:
~85K patients/year
U.S. prevalence²:
730K+ patients

400K+ TURBTs/year
in U.S.³

~800K surveillance
cystoscopies/year in
U.S.³



*1.) ACS (American Cancer Society) 2025 Cancer Facts and Figures Annual Report. 2.) SEER Cancer Stat Facts: Bladder Cancer. <https://seer.cancer.gov/statfacts/html/urinb.html>
3) Proprietary internal CPT claims data

Opportunities in Precision Diagnostics: Today and in the Future



THE
BLADDER CANCER
COMPANY

Vesica Health's Focus



Blood in the urine or other symptoms



Urologist performs initial cystoscopy

If suspected bladder cancer diagnosis,
refer to hospital for TURBT¹

AssureMDx™

Photocure's Focus



TURBT procedure, biopsy to confirm
diagnosis, remove all tumors:



BCG² or chemotherapy based on
grade or stage of bladder tumors

New therapeutics for BCG-
unresponsive patients

Regular surveillance cystoscopies according to risk-classification

Biomarkers

Vesica Health®
Noninvasive. Early. Detection.



AI BLC

CLARITAS
improve diagnosis

ARTERA



Flexible Scope

RICHARD
WOLF



NMIBC³

MIBC⁴

1) TURBT = Transurethral Resection of the Bladder Tumor; 2) BCG = Bacillus Calmette-Guerin; 3) NMIBC = Non-Muscle Invasive Bladder Cancer; 4) MIBC = Muscle-Invasive Bladder Cancer



Value-Generating Asieris Programs:

Hexvix: Commercial partnership in China

Recent News & Expectations

- Hexvix approved in China (Nov 2024); BLC equipment approved (Apr 2026)
- Commercial rollout expected to begin shortly starting with top-tier urology centers
- Structured for future upside via **manufacturing, milestones, and royalty payments on sales**

Cevira: Out-licensed worldwide rights to Asieris for development/commercialization

Recent News & Expectations

- Cevira approved in China (Mar 2026) as first non-invasive treatment for cervical precancerous lesions with commercial rollout having commenced since June 2026
- Phase III met primary endpoint, supporting efficacy in cervical HSIL
- Regulatory progress: MAA accepted in Europe, FDA pre-submission discussion ongoing
- Asieris building commercial infrastructure and partnerships in women's health oncology
- Photocure eligible for **regulatory, development, and sales milestones + royalties (multiple indications)**



THE
BLADDER CANCER
COMPANY

Q2 Financials

Consolidated Income Statement

Second Quarter 2026



THE
BLADDER CANCER
COMPANY

<i>Amounts in NOK million</i>	Q2 '26	Q2'25	Change	YTD '26	YTD '25	Change
Hexvix/Cysview Revenue	140.0	135.6	3%	279.0	261.0	7%
Milestones and Other Revenue	2.5	-		128.1	-	
Total Revenue	142.5	135.6	5%	407.1	261.0	56%
Gross Profit	132.1	125.6	5%	386.4	241.8	60%
Operating Expenses	-134.1	-110.8	21%	260.1	-225.2	15%
Reported EBITDA	-2.0	14.8		126.3	16.6	
Adjusted EBITDA	27.2	27.0		42.6	37.0	
Depreciation & Amortization	-7.4	-7.3		-15.0	-14.7	
EBIT	-9.4	7.5		111.3	1.9	
Net Financial Items	7.7	-4.9		-3.6	-8.8	
Earnings before Tax	-1.7	2.5		107.7	-6.9	
Tax Expenses	1.0	2.4		-25.0	9.3	
Net earnings	-0.7	4.9		82.7	2.5	

Revenue

- Q2 Hexvix/Cysview product revenue increased 11% at constant currency (3% incl FX) YoY driven by higher kit sales in North America and Europe. The expected decline of kits used for flexible cystoscopy in US and FX movements negatively impacted the product revenue growth
- YTD Milestone revenue includes the invoiced milestones to Asieris for the approval of Cevira in China and the MAA submission acceptance of Cevira in Europe

Operating Expenses

- Total Operating expenses increased 21% YoY to NOK 134.1 million. An increase in expenses due to merit and inflation and business development expenses related to the acquisition of Vesica Health Inc was partially offset by a favorable impact of FX.
- Operating expenses include business development expenses of NOK 21.8 million in Q2, and relate mainly to costs related to the acquisition of Vesica Health Inc.

EBITDA

- Adjusted EBITDA Q2 was NOK 27.2 million, at level with Q2 2025. YTD Adjusted EBITDA margin increased from 14% to 15%. Reported EBITDA was NOK -2.0 million (NOK 14.8 million).

Net Financial Items

- FX impacts on inter-company loan and deferred Vesica liability, offset by Ipsen earn-out payment

Segment Performance Second Quarter 2026



THE
BLADDER CANCER
COMPANY

North America Segment

<i>Amounts in NOK million</i>	Q2 '26	Q2 '25	Change	YTD '26	YTD '25	Change
Total revenues	59.3	57.5	3%	113.3	106.1	7%
Gross profit	56.4	54.8	3%	107.3	101.2	6%
% of revenue	95%	95%		95%	95%	
Direct costs	-43.8	-45.6	-4%	-90.1	-90.0	0%
Contribution ⁽¹⁾	12.6	9.2		17.2	11.2	
EBITDA	-4.3	0.4		-12.2	-10.2	
% of revenue	-7%	1%		-11%	-10%	

- Q2 revenue growth was 12% at constant currency, but was partially offset by the negative impact of FX
 - In-market unit sales increased 10%, impact of FX -9%
- Q2 direct costs decreased 4% YoY increases due to merit and inflation, and incentive accruals in line with sales increases were more than offset by a favorable impact of FX
- Q2 Contribution NOK 12.6 million, 21% of revenue (16% in the prior year)

Europe Segment

<i>Amounts in NOK million</i>	Q2 '26	Q2 '25	Change	YTD '26	YTD '25	Change
Total revenues	80.7	77.9	4%	164.1	154.6	6%
Gross profit	74.5	70.6	6%	151.1	140.4	8%
% of revenue	92%	91%		92%	91%	
Direct costs	-29.1	-28.6	4%	63.0	-60.3	5%
Contribution ⁽¹⁾	44.6	42.0		88.1	80.2	
EBITDA	25.3	25.6		53.8	44.6	
% of revenue	31%	33%		33%	29%	

- Q2 revenue increased 10% at constant currency, growth mainly driven by DACH and the High Priority Growth markets
 - In-market unit sales increased 10% (11% in DACH and 10% in High priority growth markets), impact of FX -7%
- Q2 direct costs increased 4% YoY driven by merit and inflation and increases were partially offset by FX
- Q2 Contribution NOK 44.6 million, 55% of revenue (54% in the prior year)

(1) Contribution = revenue – COGS – direct/local sales, marketing, medical and G&A costs

Cash Flow & Balance Sheet

Second Quarter 2026



THE
BLADDER CANCER
COMPANY

<i>Amounts in NOK million</i>	Q2 '26	Q2 '25	YTD '26	YTD '25
Operations Cash Flow	62.8	-6.9	63.6	-2.8
Earnings before tax	-1.7	2.5	107.7	-6.9
Depreciation & amortization	7.4	7.3	15.0	14.7
Working capital	65.7	-24.5	-65.1	-21.8
Other	-8.6	7.8	6.0	11.2
Investments Cash Flow	-80.7	0.6	-115.1	1.3
Financing Cash Flow	-12.3	-14.2	-24.9	-53.3
Net Change in Cash	-30.3	-20.4	-76.5	-54.7

<i>Amounts in NOK million</i>	30.06.26	31.12.25
Non-current assets	531.6	321.3
Inventory & receivables	207.4	146.4
Cash & short-term deposits	162.4	238.9
Equity	606.7	484.2
Long-term liabilities	193.3	116.9
Current liabilities	101.4	105.5
Total balance	901.4	707.1

Cash Flow

- Q2 cash flow from operations was NOK 62.8 million, driven by EBITDA adjusted for non-cash expenses and working capital. The working capital decrease is driven by a (partial) payment of the milestone related to the approval of Cevira in China
- Q2 cash flow from investments was NOK –80.7 million is mainly driven by the investment in Vesica Health Inc., and includes interest received and paid, other investments in tangible and intangible assets and investments in production facilities
- Q2 cash flow from financing of NOK –12.3 million includes earnout payments to Ipsen of NOK 10.8 million
- Net cash flow in Q2 was NOK –30.3 million, cash balance end of Q2 was NOK 162.4 million

Financial position

- Non-current assets include intangibles and goodwill from Ipsen transaction totaling NOK 214.9 million and from the Vesica transaction totaling NOK 232.2 million
- Long-term liabilities includes deferred Ipsen earnout totaling NOK 88.0 million and the deferred Vesica earnout totaling NOK 88.5 million
- Equity on 30 June 2026 was NOK 606.7 million, 67% of total assets



THE
BLADDER CANCER
COMPANY


Key Performance Metrics

Adjusted EBITDA Trend




THE
BLADDER CANCER
COMPANY

Yearly Adjusted EBITDA Development



YTD Adjusted EBITDA Development



Adjusted EBITDA Historically



THE
BLADDER CANCER
COMPANY

EBITDA and Adjusted EBITDA

	2026	2025	2026	2025	2025	2024	2023	2022
	Q2	Q2	YTD Jun.	YTD Jun.	Full Year	Full Year	Full Year	Full Year
<i>(All amounts in NOK 1 000)</i>								
Reported EBITDA	-1,989	14,764	126,327	16,584	28,727	49,193	55,494	-24,627
(-) Milestone Payments	0	0	-125,571	0	0	-33,713	-54,443	-18,658
(-) Non-H/C revenues and margin (includes Hivec, Cevira API and Other revenues)	-1,339	0	-1,339	0	-38	-2,199	-2,003	-739
(+) Business Development Expenses	21,806	7,758	32,163	9,534	17,392	9,327	9,241	11,014
(+) Biomarker segment expenses	2,132	0	2,132	0	0	0	0	0
(+) Severance payments	2,933	114	2,953	1,798	2,776	4,680	924	433
(+) Stock based compensation and options	3,631	4,384	5,886	9,067	20,845	16,878	19,040	23,701
(=) Total non-cash payments and non-recurring adjustments	30,502	12,257	43,134	20,399	41,013	30,885	29,205	35,147
Adjusted EBITDA	27,174	27,020	42,551	36,983	69,702	44,165	28,253	-8,876



THE
BLADDER CANCER
COMPANY

Summary

Summary of Q2 2026 results



THE
BLADDER CANCER
COMPANY

- **11% product rev. growth YoY (constant currency);** executing on key initiatives to increase sales growth.
- **Adjusted EBITDA NOK 27.2M (NOK -2.0M Reported EBITDA);** forecasting increased operating leverage while funding growth initiatives.
- **12% constant currency revenue growth in U.S. and ForTec mobile tower momentum.**
- **20% active account growth in U.S.** for rolling 12 months through Q1 2025 (**unit sales 10% growth**).
- **10% constant currency revenue growth in EU (unit sales: 11% in DACH and 10% High Priority Growth Markets).**
- Strong momentum for BLC; **Stryker system in EU** and **Richard Wolf system in China;** new data positioning **BLC as the leading precision diagnostic in the rapidly evolving NMIBC treatment landscape.**
- **Cash balance of NOK 162.4M** at end of Q2 2026; no term debt.
- Advancing several business development initiatives in **next-generation precision diagnostics, including the acquisition and integration of Vesica Health and partnership with Artera.**

Near-Term Milestones & Corporate Objectives



THE
BLADDER CANCER
COMPANY

- **2026 Financial guidance: 8-11% product revenue growth on a constant currency basis & Adjusted EBITDA margin expansion.**
- Continue **increasing Hexvix/Cysview kit utility, tower upgrades & installations;** collaborate with **ForTec on mobile tower national rollout** in U.S.; focus on growth markets & equipment launch in Europe.
- **Advance partnership with Richard Wolf** to develop and commercialize a **next-generation, state-of-the-art, 4K/High Definition Flexible BLC system** for the global markets as soon as possible.
- **Present/publish additional data from real world evidence patient registries** and other studies supporting the use of BLC with Hexvix/Cysview at; leverage Photocure's U.S. registry.
- **Increase access to BLC by supporting additional equipment manufacturers to enter the U.S. market** (FDA reclassification, other expedited pathways to market entry)
- **Support partners in China:** Hexvix and System blue equipment approved; Cevira approved.

Longer-Term Business Outlook

- Assuming Medicare reimbursement by mid-2028 and positive clinical readouts supporting commercialization, Photocure expects initial AssureMDx revenues in 2027 and positive adjusted EBITDA contribution from AssureMDx operations by 2030, with market access and commercialization costs funded through free cash flow.
- Modest Vesica Health operating losses expected in the near-term, quickly ramping to segment EBITDA margins north of 30%.
- The consolidated business is expected to accelerate revenue growth from a standalone mid-to-high teens CAGR to above 25% CAGR from 2026-2030, while maintaining strong profitability with consolidated adjusted EBITDA margins above 25% by 2030 and additional upside potential.
- Importantly, completion of FDA down-classification, entry of additional scope manufacturers into the U.S. market including reintroduction of flexible scopes, will provide further upside to the standalone growth outlook.



THE
BLADDER CANCER
COMPANY



Q&A



THE
BLADDER CANCER
COMPANY

